Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer by Maurizio Capuozzo, Mariachiara Santorsola, Monica Ianniello, Francesco Ferrara, Andrea Zovi, Nadia Petrillo, Rosa Castiello, Maria Rosaria Fantuz, Alessandro Ottaiano, Giovanni Savarese

Get full text

Complications and Functional Results of Surgery for Locally Advanced Prostate Cancer by S. G. Joniau, A. A. Van Baelen, C. Y. Hsu, H. P. Van Poppel

Get full text

New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication by Jennifer H. Gunter, Phoebe L. Sarkar, Amy A. Lubik, Colleen C. Nelson

“…We provide an update on current treatments for advanced prostate cancer and discuss whether metabolic dysfunction, developed during ADT, provides a unique therapeutic window for rapid translation of insulin-sensitising medication as combination therapy with antiandrogen targeting agents for the management of advanced prostate cancer.…”
Get full text

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies by Tilman Todenhöfer, Arnulf Stenzl, Lorenz C. Hofbauer, Tilman D. Rachner

Get full text

Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer by Alacia M. Voth, John G. Alford, Edward W. Swim

“…One of the most important treatments for advanced prostate cancer has become androgen deprivation therapy (ADT). …”
Get full text

Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer by Manish Kohli, Rui Qin, Rafael Jimenez, Scott M. Dehm

“…This translational progress from “bench to bed-side” has resulted in an enlarging repertoire of novel and traditional drug choices now available for use in advanced prostate cancer therapeutics, which has had a positive clinical impact in prolonging longevity and quality of life of advanced prostate cancer patients. …”
Get full text

Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers by Diego J. Laderach, Lucas Gentilini, Felipe M. Jaworski, Daniel Compagno

“…A better understanding of multimolecular interactions involved in tumor dissemination is required to identify new effective therapies for advanced prostate cancer (PCa). Several groups investigated protein-glycan interactions as critical factors for crosstalk between prostate tumors and their microenvironment. …”
Get full text

Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study by Alexandre Peltier, Fouad Aoun, Vincent De Ruyter, Patrick Cabri, Roland Van Velthoven

Get full text

Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer by Sean Woolen, Cameron Holzmeyer, Emily Nesbitt, Paul F. Siami

Get full text

Indian consensus statements on the management of small renal masses, non‐muscle invasive bladder cancer and high‐risk/locally advanced prostate cancer by Simon Hughes, Rajesh Nair, Bhav Radia, Ravimohan S. mavuduru, Prokar Dasgupta, Amit Ghose

“…A modified Delphi method was used to provide a framework for the systematic development of India‐centric guidelines for the management of three uro‐oncology disease states: small renal masses, non‐muscle invasive bladder cancer and high‐risk/locally advanced prostate cancer.…”
Get full text

Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only by Stefan Latz, Christian Fisang, Wolfram Ebert, Stefan Orth, Dirk G. Engehausen, Stefan C. Müller, Ralf Anding

Get full text

Knowledge and understanding of information after taking decision to participate or not in a randomized trial of surgery vs radiotherapy among patients with locally advanced prostate cancer – an observational study by Yvonne Brandberg, Olof Akre, Mia Bergenmar

“…Patients: After the decision about participation in the randomized study, ‘Surgery versus radiotherapy for locally advanced prostate cancer’ (SPCG-15), patients were sent questionnaires (‘Quality of Informed Consent’, EORTC QLQ-INFO25). …”
Get full text

CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells by Kiel T. Tietz, Braedan M. McCluskey, Conor R. Miller, Yingming Li, Sarah A. Munro, Scott M. Dehm

“…Summary: Localized prostate cancer can be cured by radiation or surgery, but advanced prostate cancer continues to be a clinical challenge. …”
Get full text

Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer by Amit D. Raval, Malcolm D. Mattes, Suresh Madhavan, Xiaoyun Pan, Wenhui Wei, Usha Sambamoorthi

“…A significantly lower percentage of metformin users were diagnosed with advanced prostate cancer as compared to nonusers (4.7% versus 6.7%, p<0.03). …”
Get full text

GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy by Shikha Patel, Bhagawati Saxena, Priti Mehta, Sarfaraz K. Niazi

“…These characteristics qualify GnRH antagonists as revolutionary therapy for diseases such as advanced prostate cancer, endometriosis, uterine fibroids, and in vitro fertilization procedures. …”
Get full text

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy by Matthew E. Johnson, Mark K. Buyyounouski

“…Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer. Androgen deprivation has been associated with a wide range of iatrogenic effects impacting a variety of body systems including metabolic, musculoskeletal, cardiovascular, neurocognitive, and sexual. …”
Get full text

Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment by Jiang H

“…Bone metastasis occurs in up to 90% of advanced prostate cancer patients, metastatic prostate cancer is generally considered a non-curative condition which can impact quality of life. …”
Get full text

Interactions between key genes and pathways in prostate cancer progression and therapy resistance by Fan Wu, Hengsen Zhang, Miaomiao Hao

“…The primary obstacle to curing advanced prostate cancer is the absence of comprehensive treatment strategies that effectively target the highly heterogeneous tumors at both genetic and molecular levels. …”
Get full text

Rubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer by Henry M. Rosevear, Andrew J. Lightfoot, Michael A. O'Donnell, Charles E. Platz, Stefan A. Loening, Charles E. Hawtrey

“…Flocks' use of colloidal gold for the treatment of locally advanced prostate cancer offered short- and long-term survival benefits compared to other contemporary treatments.…”
Get full text

xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis. by Elena D Wilhelm, Jaroslaw T Dankert, Marc Wiesehöfer, Sven Wach, Mathias Wagner, Martin Spahn, Marianna Kruithof-de Julio, Gunther Wennemuth

“…Moreover, immunostaining revealed precise xCT expression in neuroendocrine cells, ranging from fetal, healthy juvenile, and adult prostate tissue to benign prostatic hyperplasia and finally advanced prostate cancer. This study explores the relevance and function of xCT and AL122023.1 in the prostate and exposes xCT as a potential marker or therapeutic target in high-risk prostate cancer.…”
Get full text